European Drug Utilization Conference 2025

Bridging data, policy and patients in drug utilization research









This project has received funding from the European Union's Horizon Europe Research and Innovation Actions under grant no. 101095479 (More-EUROPA). Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union nor the granting authority. Neither the European Union nor the granting authority can be held responsible for them.



Sonia Zebachi

EUROPEAN DRUG
UTILIZATION
CONFERENCE
2025
Bridging Data, Policy & Patients in Drug
Utilization Research

Navigating the Real World: A Scoping Review of Structured Frameworks to Effectively Identify, Evaluate, and Select Real-World Data Sources for Fit-for-Purpose Studies

Sonia Zebachi¹, Julien Tanniou¹, Elisabeth Bakker², Sieta T. de Vries², Rossella Di Bidino⁴, Entela Xoxi⁵, Anna Glaser³, Gianluigi Savarese⁶, Jan Hillert³, Peter G.M. Mol², Kelly Plueschke⁷, Billy Amzal¹, Ghinwa Y. Hayek¹, Jeverson Moreira¹

¹Quinten Health, Paris, France, ²University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands, ³Karolinska Institute - Department of Clinical Neuroscience, Stockholm, Sweden, ⁴Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, ⁵Alta Scuola di Economia e Management dei Sistemi Sanitari (ALTEMS) - Università Cattolica del Sacro Cuore, Rome, Italy, ⁶Karolinska Institute – Department of Medicine, Stockholm, Sweden, ⁷European Medicines Agency (EMA), Amsterdam, Netherlands

QR code to abstract will be added by conference team

European Drug Utilization Conference 2025

Bridging data, policy and patients in drug utilization research





Aim

- Identify "structured" frameworks (tools/methods) to identify, and/or assess, and/or select "fit-forpurpose" RWD for regulatory purposes with a special focus on registries.
- Perform a comparative analysis using the criteria of the identified structured frameworks.

Methods

- Scoping review [2013-2023] through PubMed, Web of Science and Scopus.
- Combination of search terms: RW, registries, fit-for-purpose or fit-for-use, and regulatory.
- Definition of 'fit-for-purpose': whether data seems of sufficient quality to generate relevant and reliable evidence to inform regulatory decision-making.

Results

- 9 frameworks identified from 54 articles, none allowing RWD discoverability (potential detection).
- Structured Preapproval and Postapproval Comparative study design (SPACE), Structured Process to Identify Fit-For-Purpose Data (SPIFD) 1 & 2, PICOTS (Populations, Interventions, Comparators, Outcome(s), Timing and Setting), MATURITY, PICOTS – 3-step conceptual mode for oncology, RWD-Cockpit, Registry Evaluation and Quality Standards Tool (REQUEST), and Authentic Transparent Relevant Accurate Track-Record (ATRACTR).

Figure 1. List of criteria captured across the nine identified frameworks

Study design elements

- Research question
 Outcome(s)
- Population
- Inclusion/exclusion criteria
- Comparator
- Exposure
- Setting(s)
- Length of follow-up
- Control of confounding
- Sample size
- Study design typeEstimator(s)

REQueST, SPACE/SPIFD/SPIFD2, PICOTS (EHR, onco)

Data quality

- Data content
- Completeness
- Coverage
- Accuracy
- Validity
- Consistency
- PlausibilityPeriodicity
- Conformance to a common data model

ATRACTR, REQueST, Maturity, PiCOTS (onco)

Practical & legal aspects

- Data linkageTransparency
- Primary/secondary use of data
- Data protection policies
- Governance
- Privacy rules
- Access (rights/methods)
- Timelines (contract, data access)
- Budget

REQueST, SPIFD2, ATRACTR, RWD-Cockpit

Conclusion

- Several frameworks for RWD assessment, choice of use should be based on the prioritised criteria.
- Strong need for a tool **combining discoverability and assessment** for 'fit-for-purpose' RWD (cf. **More-Europa Tool**)